Lajos Pusztai, MD, DPhil, Member
BCRF Scientific Advisory Board
Lajos Pusztai received his Doctor of Medicine (MD) degree from the Semmelweis University of Medicine in Budapest, Hungary in 1987. Subsequently he studied at the University of Oxford in England where he received his Doctor of Philosophy degree (D.Phil.) in 1993. He completed his graduate medical training in the US and joined the faculty of the University of Texas MD Anderson Cancer Center (MDACC) in 1999, where he was Professor of Medicine and led the pharmacogenomic program in the Department of Breast Medical Oncology. Dr. Pusztai is currently Professor of Medicine and Chief of Breast Medical Oncology Division at Yale School of Medicine. He is also Co-Director of the Genomics Program at Yale Cancer Center.
Dr Pusztai is principal investigator of several clinical trials investigating new drugs and potential response markers. His research is supported by grants from the National Cancer Institute, the US Department of Defense, the American Society of Clinical Oncology, The Breast Cancer Research Foundation and philanthropic research grants.
He received several international awards including the Soros Scholarship by the George Soros Fundation, New York, the Overseas Research Students Award of the Vice-chancellors and Principals of the Universities of the United Kingdom, a Career Development Award from the US Department of Defense Breast Cancer Research Program and the MD Anderson Aventis Drug Development Award. He has published over 150 peer-reviewed articles on the biology and treatment of breast cancer. He is senior editor of a book on cell proliferation and cancer and also contributed chapters to books such as the Oxford Textbook of Pathology, Computational and Statistical Approaches to Genomics, Molecular Oncology of Breast Cancer, Molecular Pathology in Clinical Practice and the Textbook of Breast Cancer.
Dr. Pusztai's research focuses on the developing pharmacogenomic markers of response to therapy and identifying methods to select the optimal treatment for individual patients. His group has proposed new clinical trial designs for predictive marker evaluation, introduced new pathologic measurements of residual cancer after neoadjuvant chemotherapy, created web-based chemotherapy response prediction models based on routine clinical variables and proposed genomic markers of chemo- and endocrine-therapy sensitivity.
|
